12:00 AM
 | 
Feb 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lexgenleucel-T: Phase I/II data

Data from 61 patients enrolled in 3 U.S. Phase I and II trials showed that of 8,007 integrations of VRX496, there were no insertions near...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >